GUILLAIN-BARRE SYNDROME

 

GUILLAIN-BARRE SYNDROME

 

DEFINITION:

An acquired demyelinating disorder of the peripheral nervous system characterized by progressive motor weakness and areflexia.

EPIDEMIOLOGY:

  • incidence: 0.6-1.9/100,000 (adult & childhood cases)
  • age of onset:
    • patients are <20 years of age in 30% of cases
      • 2/3rds of these are in children <8 years of age
      • rare in children <2 years of age
  • risk factors:
    • M > F (3:2)
    • season: fall and winter

PATHOGENESIS:

  • 50-70% of cases occur within 4 weeks of an antecedent illness (usually an upper respiratory tract infection or GI infection by CMV or EBV) -> autoimmune response towards peripheral nerves (via cell- and humorally-mediated immune mechanisms) -> focal areas of inflammation and demyelination of motor (+/- sensory) nerves - also may occur after hepatitis, immunizations, insect stings, surgery, viral exanthems, and other illnesses
  • Campylobacter jejuni and Mycoplasma pneumoniae have been implicated

PATHOLOGY:

  • widespread areas of focal inflammation and demyelination

1. Sites of Attack

  • most common
    • proximal nerve roots at junction of dorsal & ventral nerve roots at the site of dural attachment
  • less common
    • lumbar and brachial plexuses
    • peripheral and cranial nerves
  • rarely affected
    • dorsal root or ganglia
    • sympathetic chain

2. Inflammatory Response

  • inflammatory cells: macrophages and lymphocytes
  • these cells attack the myelin sheath of Schwann cells leaving the Schwann cells and axons undisturbed
  • complications:
    • surrounding axons may be secondarily injured in areas of intense inflammation causing chromotolysis and neurono-phagia of the anterior horn cells
    • inflammation at sites of dural attachment may cause breakdown of the blood-brain barrier resulting in transudation of plasma proteins into the CSF
    • insertion of macrophages beneath the lamellae of the myelin sheath stripping away long sections -> focal demyelination
    • -> conduction block

CLINICAL FEATURES:

1. Neurological Manifestations

1. Progressive Motor Weakness

  • usually ascends from legs to arms and may involve truncal and finally bulbar musculature (rarely descends)
  • may present as a disturbance of gait or acute ataxia
  • symmetrical with weakness greater distally than proximally
  • may lead to transient quadriplegia
  • respiratory paralysis in 18%
  • cranial nerve palsies in 30-40%:
    • 7th - facial diplegia most common
    • 9&10 - dysphagia 2nd most common
    • all may be involved rarely except the olfactory nerve
  • if extraocular muscle involvement think of Miller-Fisher syndrome

2. Reflexes

  • symmetric areflexia or marked hyporeflexia
  • may be mildly asymmetric initially
  • may rarely precede motor weakness or may be a late finding

3. Sensation

  • loss of position and vibratory sensation
  • occasionaly pain or parethesias
  • insidious symptoms may precede motor weakness

4. Autonomic Dysfunction

  • bowel and bladder dysfunction
    • transient and not seen at onset
  • cardiovascular instability:
    • hypertension, orthostatic hypotension, tachyarrhythmias

INVESTIGATIONS:

1. Cerebral Spinal Fluid

  • dissociation of elevated protein with lack of cellular response is highly suggestive of Guillain-Barre syndrome
  • elevated protein
    • may be undetectable in 1st week of illness
    • often peaks at 3-4 weeks
    • proteins similar to those in plasma as well as Ig's and oligoclonal bands
  • slight pleocytosis (<10 cells/ul)

2. Electrodiagnostic

1. Nerve Conduction Velocity

  • may be reduced to 60% of normal
    • detected in 50% during first 2 weeks
    • " 85% during 3rd week
  • due to segmental demyelination -> conduction block
  • may involve motor and sensory nerves
  • distal > proximal initially (in 1st week)

2. Somatosensory Evoked Responses

  • altered reflecting proximal root involvement

3. EMG

  • no changes except decreased recruitment pattern

MANAGEMENT:

1. For Guillain-Barre Syndrome

1. Plasmapheresis

  • may be beneficial in children with rapid deterioration or in those needing intubation

2. Supportive

1. Multidisciplinary Approach

  • in an ICU setting
  • Peaditrician, Intensivist, Neurologist, OT, PT, Psychology
  • moniter neuromuscular, respiratory, cardiovascular status

2. Intubation

  • indications for
    • respiratory distress/failure
    • cardiovascular instability
    • decrease in vital capacity to 50% of normal
    • progression to dysphagia, shoulder or facial paresis may indicate need for intubation
  • usual duration: 2-8 weeks with consideration of tracheostomy with lack of improvement after 2 weeks

3. Prognosis

1. Natural History

  • usually a benign clinical course with recovery with 2-3 weeks with recovery of muscle function inversely related to onset of symptoms (i.e., bulbar -> arms -> legs)
  • complete recovery:
    • 50% within 6 months
    • 60-70% within 12 months

2. Complications

  • 10% with permanent deficits
  • 7% will relapse
  • 3-4% mortality
  • chronic forms of Guillain-Barre:
    • Chronic Relapsing Polyradiculoneuropathy
    • Chronic Unremitting Polyradiculoneuropathy

3. Poor Prognostic Indicators

  • extensive denervation on EMG
  • increased duration of time from maximal deficit to onset

 

 

Pediatric Database - GUILLAIN-BARRE SYNDROME

Pediatric Organization - Pedbase [at] Gmail.com